What Swarm Oncology does

Swarm Oncology is a UK-based clinical-stage biotechnology company founded in 2022 that develops personalized T cell therapies for patients with advanced and metastatic solid cancers. The company operates from registered offices in London (at the Delin Ventures address) and runs its primary R&D laboratories across two University of Glasgow sites — the Sir Graeme Davies Building and the Clinical Innovation Zone at Queen Elizabeth University Hospital. Its stated customer segment is patients with metastatic solid tumours, where 82.4% of patients die from their disease, and where existing immunotherapies are limited by toxicity, inefficacy in solid tumours, and reliance on pre-existing immune responses.

The company's core product is Swarm-T, an autologous antigen-specific T cell therapy manufactured from patients who have received personalized cancer vaccinations. The platform combines in vivo priming (a vaccine that primes tumour-antigen-specific T cells) with a proprietary T cell isolation process that discards non-effective immune cells and enriches the fittest antigen-specific T cells from peripheral blood. The resulting cell product is described as phenotypically optimized, cost-efficient, and durable. The lead pipeline candidate, SWM-XXX, targets multiple solid tumour types and is positioned at preclinical / pre-IND development. Swarm has completed GMP technology transfer to Cellex Cell Professionals GmbH, which holds German Manufacturer's Authorisation for clinical-grade drug product manufacturing, de-risking first-in-human supply.

Swarm Oncology is pre-revenue and pre-commercial. Its revenue model contemplates one-time licensing of cell therapy products upon regulatory approval and commercialization, with pricing not publicly disclosed and typical of value-based cell therapy negotiations. Go-to-market is enterprise-focused, relying on research collaborations with leading hospitals (including a US hospital partnership for patient sample analysis and platform validation) and on CDMO partnerships for manufacturing. The company is funded by Delin Ventures via an extended £6.1M seed round (March 2026) and is led by CEO Martin Olin, CSO Prof. John Campbell, COO Shree Patel, and Chairman Bernhard Ehmer, with a broad scientific and clinical advisory board.

Name

Swarm Oncology

Legal name

Swarm Oncology Limited

Website

https://swarmoncology.bio

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

T Cell Immunotherapy / Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Adoptive cell therapy
• T cell immunotherapy
• Solid tumor treatment
• Personalized cancer vaccines
• Autologous cell therapy

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. T Cell Therapy Products: Autologous antigen-specific T cell adoptive therapies for solid organ cancers. Revenue will be generated from clinical-stage cell therapy products once approved and commercialized.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Swarm Oncology develops personalized autologous antigen-specific T cell therapies for patients with advanced and metastatic solid cancers. Its Swarm-T product is manufactured from patients who have received personalized cancer vaccinations, isolating and expanding tumour-targeting T cells that are phenotypically optimized, cost efficient, and durable. The Swarm T Cell Therapy Platform combines in vivo priming, antigen-specific T cell isolation, and GMP-compliant manufacturing, with lead pipeline candidate SWM-XXX progressing through preclinical and Phase I development.

Product overview

Swarm Oncology is a biotechnology company developing personalised T cell therapies for advanced solid cancers. The company's core offering is the Swarm-T product, an autologous antigen-specific T cell therapy that works in combination with in vivo priming (personalised cancer vaccines). The Swarm T Cell Therapy Platform enables the isolation, expansion, and manufacturing of potent, early memory T cells that are highly targeted and durable. The lead pipeline candidate is SWM-XXX for multiple solid tumour types. The platform is designed to improve upon existing immunotherapy approaches by generating a powerful, sustained cellular immune attack on advanced solid cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• Swarm-T An autologous antigen-specific T cell therapy product manufactured from patients who have received personalised cancer vaccinations. The therapy isolates and expands tumour-targeting T cells that are phenotypically optimized, cost efficient, and durable, intended for treatment of advanced solid cancers.
• Swarm T Cell Therapy Platform A technology platform designed to unlock the full potential of personalised T cell therapies through a combination of in vivo priming, antigen-specific T cell isolation, and product manufacturing capabilities. The platform delivers cell therapies that are highly targeted, phenotypically optimized, cost efficient, and durable, with completed GMP technology transfer to a CDMO enabling clinical-grade manufacturing.
• SWM-XXX Lead pipeline candidate of Swarm Oncology targeting multiple solid tumour types, currently in preclinical/Pre-IND/Phase I development stages as an autologous antigen-specific T cell therapy for advanced solid cancers.

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Cellex Cell Professionals GmbHcoreTechnology or Integration · 5 March 2026Swarm Oncology completed GMP technology transfer to Cellex Cell Professionals GmbH, which has received German Manufacturer's Authorisation enabling GMP-compliant production for clinical trials. This partnership enables Swarm to manufacture clinical-grade drug products for first-in-human studies.
• Leading US HospitalcoreStrategic or Co-development Partner · 28 October 2025Research collaboration with a leading US hospital to enhance the manufacturing and efficacy of T cell therapies for solid cancers. The collaboration involves analyzing patient samples to validate their platform that aims to improve cancer vaccine outcomes. Includes immune profiling and research-scale manufacturing of personalized T-cell treatments.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Turnstone Biologics: Clinical-stage biotech developing tumor-infiltrating lymphocyte (TIL) and selected T cell therapies for solid tumors. Comparable autologous T cell platform targeting advanced solid cancers.
• Neogene Therapeutics: Personalized TCR-T cell therapy developer for solid tumors (acquired by AstraZeneca). Closely comparable in approach — isolating and engineering tumor-specific TCRs from patient T cells for autologous therapy.
• Achilles Therapeutics: UK-based clinical-stage biotech developing personalized neoantigen-targeted T cell therapies for solid tumors. Closest direct peer given Swarm's autologous, patient-specific T cell platform targeting solid cancers.
• Immunocore: UK-based biotech developing TCR-based immunotherapies (ImmTAC platform) for solid tumors and infectious disease. Comparable as a T cell receptor-based oncology company targeting solid tumor antigens.
• Immatics: Clinical-stage biotech developing TCR-based immunotherapies and adoptive cell therapies for solid tumors. Directly comparable in targeting tumor-specific antigens via T cell approaches.
• Adaptimmune: Clinical-stage cell therapy company developing engineered TCR-T cell therapies for solid tumors. Directly comparable in modality (T cell therapy, solid tumor focus) though using engineered receptors versus Swarm's naturally primed T cells.
• Iovance Biotherapeutics: Commercial-stage cell therapy company with the first FDA-approved TIL therapy (lifileucel) for melanoma. Comparable as an autologous adoptive T cell therapy developer for solid tumors with proven manufacturing scale.
• Lyell Immunopharma: Clinical-stage cell therapy company focused on engineering T cells for solid tumors with enhanced persistence and resistance to exhaustion. Comparable autologous T cell therapy approach with solid tumor focus.

Broad incumbents

• Moderna: Major mRNA biotech developing personalized cancer vaccines (mRNA-4157/V940) in partnership with Merck. Indirectly comparable — success of Moderna's personalized vaccines would validate the in vivo priming concept Swarm depends on.
• BioNTech: Large biotech with leading personalized neoantigen cancer vaccine programs (BNT122) and a growing cell therapy pipeline. Comparable as a personalized cancer immunotherapy incumbent whose vaccine approach underpins Swarm's in vivo priming strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swarm Oncology